SCHEMBL2640824

SCHEMBL2640824

O=C(O)C(O)CCCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC7 Q8WUI4 6/20 0.53
HDAC1 Q13547 5/20 0.53
MMP2 P08253 2/20 0.52
MMP9 P14780 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MAPT P10636 1/20 0.51
RAB9A P51151 1/20 0.51
ALDH1A1 P00352 4/20 0.50
HDAC8 Q9BY41 3/20 0.50
HDAC3 O15379 2/20 0.50
HDAC4 P56524 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC10 Q969S8 2/20 0.50
HDAC11 Q96DB2 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
HDAC9 Q9UKV0 2/20 0.50
HDAC5 Q9UQL6 2/20 0.50
HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2640823 1.00 HDAC7 (0.53) HDAC7HDAC1MMP2MMP9SMN1; SMN2
SCHEMBL11686163 0.95 HDAC1 (0.59) HDAC7HDAC1MMP2MMP9SMN1; SMN2
SCHEMBL1286243 0.90 ALDH1A1 (0.55) HDAC7HDAC1MMP2MMP9SMN1; SMN2
SCHEMBL1781793 0.90 ALDH1A1 (0.55) HDAC7HDAC1MMP2MMP9SMN1; SMN2
SCHEMBL9219366 0.85 MMP2 (0.55) HDAC7HDAC1MMP2MMP9SMN1; SMN2
SCHEMBL7898753 0.83 HDAC7 (0.52) HDAC7HDAC1MMP2MMP9SMN1; SMN2
SCHEMBL9191639 0.83 HDAC1 (0.52) HDAC7HDAC1MMP2MMP9SMN1; SMN2
SCHEMBL11093898 0.83 HDAC1 (0.52) HDAC7HDAC1MMP2MMP9SMN1; SMN2
SCHEMBL3359985 0.83 HDAC7 (0.52) HDAC7HDAC1MMP2MMP9SMN1; SMN2
SCHEMBL7026832 0.83 HDAC1 (0.52) HDAC7HDAC1MMP2MMP9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106905386-B Aminoglycoside derivatives 莱姆派克斯制药公司 2020-03-27 CN disclosed
EP-2569324-B9 AMINOGLYCOSIDE DERIVATIVES REMPEX PHARMACEUTICALS INC (US) 2018-03-28 EP disclosed
EP-2569324-B1 AMINOGLYCOSIDE DERIVATIVES REMPEX PHARMACEUTICALS INC (US) 2017-12-06 EP disclosed
US-8906868-B2 Aminoglycoside derivatives REMPEX PHARMACEUTICALS, INC. (US) 2014-12-09 US disclosed
CN-103003293-A Aminoglycoside Derivatives REMPEX PHARMACEUTICALS INC 2013-03-27 CN disclosed
EP-2569324-A1 AMINOGLYCOSIDE DERIVATIVES Rempex Pharmaceuticals, Inc. (US) 2013-03-20 EP disclosed
US-20130059808-A1 AMINOGLYCOSIDE DERIVATIVES REMPEX PHARMACEUTICALS, INC. (US) 2013-03-07 US disclosed
WO-2011143497-A1 AMINOGLYCOSIDE DERIVATIVES REMPEX PHARMACEUTICALS, INC. (US) 2011-11-17 WO disclosed
US-4104372-A ANTIBACTERIAL ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) 1978-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059808-A1 AMINOGLYCOSIDE DERIVATIVES AMPD3, ALG8, MRPL21 HDAC7 1220/4885HDAC1 1293/4885MMP2 3754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.